CD40表达与低级别及高级别胶质瘤总生存和无进展生存负相关
研究基于患者样本(74例II级、36例III级胶质瘤和40例GBM)及TCGA数据,用实时PCR分析CD40/CD40L表达。发现CD40高表达与LGG和GBM患者更短的无进展生存和总生存显著相关,且CD40在IDH野生型GBM中表达高于IDH突变型;CD40L表达与生存无相关性。
要点
- CD40高表达与LGG和GBM患者更短的无进展生存和总生存显著相关。
- CD40在IDH野生型GBM中表达高于IDH突变型GBM。
- CD40L表达与生存数据无相关性。
核心结论
- CD40高表达与低级别和高级别胶质瘤的不良结局显著相关,并在IDH野生型GBM中过表达。
研究设计与样本
- 基于患者来源样本(74例II级胶质瘤、36例III级胶质瘤和40例GBM)的实时聚合酶链反应表达分析,并以TCGA开放数据中「brain lower grade glioma」和「glioblastoma」队列的mRNA表达作为验证数据集。
主要发现
- LGG中CD40过表达患者无进展生存缩短(43 vs. 29个月;风险比0.5715;P=0.0262),总生存缩短(116 vs. 54个月;风险比0.3431;P<0.0001)。
- 复发II级胶质瘤较原发II级胶质瘤CD40表达更高(P=0.0028)。
- GBM中CD40为总生存的负性标志物(12 vs. 10个月;风险比0.5178;P=0.0491)。
- IDH野生型GBM中CD40表达高于IDH突变型GBM。
- TCGA数据支持上述发现,LGG和GBM中PFS和OS结果相似;CD40L表达与生存数据无相关性。
临床怎么用
- CD40表达或可作为低级别和高级别胶质瘤预后评估的候选生物标志物。
- IDH野生型GBM中CD40表达更高,提示其与分子分型的潜在关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-grade gliomas (LGGs) are known to progress to glioblastoma (GBM), decreasing the chances of survival. The tumor necrosis factor receptor CD40 and its ligand CD40L have shown value as biomarkers for GBM. The present study evaluated the role of CD40/CD40L in LGG and GBM in differentiating isocitrate dehydrogenase (IDH) wild-type and IDH-mutant GBM. METHODS: The present study was based on patient-derived samples (74 grade II gliomas, 36 grade III gliomas, and 40 cases of GBM) and expression analysis using real-time polymerase chain reaction. Open-access data from The Cancer Genome Atlas (TCGA) and the strong cohorts of TCGA data sets "brain lower grade glioma" and "glioblastoma" were used to run the analysis on mRNA expression as a validation data set. RESULTS: We found that patients with LGG and CD40 overexpression experienced shorter progression-free survival (43 vs. 29 months; hazard ratio, 0.5715; P = 0.0262) and overall survival (116 vs. 54 months; hazard ratio, 0.3431; P < 0.0001). Consistently, relapsed grade II glioma showed greater CD40 expression compared with primary grade II glioma (P = 0.0028). Just as with LGG, CD40 was a negative marker for overall survival in GBM (12 vs. 10 months; hazard ratio, 0.5178; P = 0.0491). In this context, we found greater CD40 expression in IDH wild-type GBM than in IDH-mutant GBM. The data obtained from TCGA supported our findings, with similar results for PFS and OS in LGG and GBM. CD40L expression showed no correlation with the survival data. CONCLUSION: High CD40 expression showed a significant correlation with poor outcomes for both LGG and GBM and was overexpressed in IDH wild-type GBM.
引用
- Werner JM, Kuhl S, Ulrich K, et al. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas. World Neurosurg. 2019. PMID: 31125770. doi:10.1016/j.wneu.2019.05.112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。